Chemical Chaperones Exceed the Chaperone Effects of RIC-3 in Promoting Assembly of Functional α7 AChRs

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kuryatov, Alexander ^a   Mukherjee, Jayanta ^a   Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; BUNGAROTOXIN RECEPTOR; CHAPERONE; PROTEIN RIC 3; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR CHAPERONES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS;

EID: 84876550044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062246     Document Type: Article

References (42)

1. Faghih R, Gopalakrishnan M, Briggs CA, (2008) Allosteric modulators of the α7 nicotinic acetylcholine receptor. J Med Chem 51: 701-712.
2. Malysz J, Gronlien JH, Anderson DJ, Hakerud M, Thorin-Hagene K, et al. (2009) In vitro pharmacological characterization of a novel allosteric modulator of α7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonami de (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330: 257-267.
3. Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, et al. (2008) Preclinical characterization of A-582941: a novel α7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther 14: 65-82.
4. Young GT, Zwart R, Walker AS, Sher E, Millar NS, (2008) Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A 105: 14686-14691.
5. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, et al. (1998) Chronic nicotine treatment up-regulates human α3β2 but not α3β4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 273: 28721-28732.
6. Kuryatov A, Luo J, Cooper J, Lindstrom J, (2005) Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol 68: 1839-1851.
7. Kuryatov A, Onksen J, Lindstrom JM, (2008) Roles of accessory subunits in α4β2* nicotinic receptors. Mol Pharmacol 74: 132-143.
8. Tumkosit P, Kuryatov A, Luo J, Lindstrom J, (2006) β3 subunits promote expression and nicotine-induced up-regulation of human nicotinic α6* nicotinic acetylcholine receptors expressed in transfected cell lines. Mol Pharmacol 70: 1358-1368.
9. Fitch RW, Xiao Y, Kellar KJ, Daly JW, (2003) Membrane potential fluorescence: a rapid and highly sensitive assay for nicotinic receptor channel function. Proc Natl Acad Sci USA 100: 4909-4914.
10. Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, et al. (2010) Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain 149: 33-49.
11. Millar NS (2008) RIC-3: a nicotinic acetylcholine receptor chaperone. Br J Pharmacol 153 Suppl 1, S177-183.
12. Millar NS, Gotti C, (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 56: 237-246.
13. Boulin T, Gielen M, Richmond JE, Williams DC, Paoletti P, et al. (2008) Eight genes are required for functional reconstitution of the Caenorhabditis elegans levamisole-sensitive acetylcholine receptor. Proc Natl Acad Sci U S A 105: 18590-18595.
14. Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, et al. (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 46: 595-607.
15. Perlmutter DH, (2002) Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 52: 832-836.
16. Rubenstein RC, Zeitlin PL, (2000) Sodium 4 phenylbutyrate downregulates HSC70. Implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 278: C259-267.
17. Maestri NE, Brusilow SW, Clissold DB, Bassett SS, (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855-859.
18. Rubenstein RC, Zeitlin PL, (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157: 484-490.
19. Butler R, Bates G, (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7: 784-796.
20. Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J, (1994) Human α7 acetylcholine receptor: cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional α7 homomers expressed in Xenopus oocytes. Mol Pharmacol 45: 546-554.
21. Williams ME, Burton B, Urrutia A, Shcherbatko A, Chavez-Noriega LE, et al. (2005) RIC-3 promotes functional expression of the nicotinic acetylcholine receptor α7 subunit in mammalian cells. J Biol Chem 280: 1257-1263.
22. Mukherjee J, Kuryatov A, Moss SJ, Lindstrom JM, Anand R, (2009) Mutations of cytosolic loop residues impair assembly and maturation of α7 nicotinic acetylcholine receptors. J Neurochem 110: 1885-1894.
23. Cooper ST, Harkness PC, Baker ER, Millar NS, (1999) Up-regulation of cell-surface α4β2 neuronal nicotinic receptors by lower temperature and expression of chimeric subunits. J Biol Chem 274: 27145-27152.
24. Conroy WG, Liu QS, Nai Q, Margiotta JF, Berg DK, (2003) Potentiation of α7-containing nicotinic acetylcholine receptors by select albumins. Mol Pharmacol 63: 419-428.
25. Atmaca A, Maurer A, Heinzel T, Gottlicher M, Neumann A, et al. (2004) A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer. J Clin Oncol 22: 3169.
26. Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, et al. (2009) Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci. 29: 13898-908.
27. Castillo M, Mulet J, Aldea M, Gerber S, Sala S et al. (2009) Role of the N-terminal alpha-helix in biogenesis of alpha7 nicotinic receptors. J Neurochem. 108, 1399-409.
28. Cooper ST, Millar NS, (1997) Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit. J Neurochem 68: 2140-2151.
29. Kassner PD, Berg DK, (1997) Differences in the fate of neuronal acetylcholine receptor protein expressed in neurons and stably transfected cells. J Neurobiol 33: 968-982.
30. Lansdell SJ, Gee VJ, Harkness PC, Doward AI, Baker ER, et al. (2005) RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells. Mol Pharmacol 68: 1431-1438.
31. Gopalakrishnan M, Buisson B, Touma E, Giordano T, Campbell JE, et al. (1995) Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur J Pharmacol 290: 237-246.
32. Peng JH, Lucero L, Fryer J, Herl J, Leonard SS, et al. (1999) Inducible, heterologous expression of human α7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Brain Res 825: 172-179.
33. Vallés AS, Roccamo AM, Barrantes FJ, (2008) RIC-3 chaperone-mediated stable cell-surface expression of the neuronal α7 nicotinic acetylcholine receptor in mammalian cells. Acta Pharmacol Sin 6: 818-827.
34. Zhao L, Kuo YP, George AA, Peng JH, Purandare MS, et al. (2003) Functional properties of homomeric, human α7-nicotinic acetylcholine receptors heterologously expressed in the SH-EP1 human epithelial cell line. J Pharmacol Exp Ther 305: 1132-1141.
35. Roncarati R, Seredina T, Jow B, Jow F, Papini S, et al. (2008) Functional properties of α7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. Assay Drug Dev Technol 6: 181-193.
36. Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, et al. (2004) Stable expression and characterization of a human α7 nicotinic subunit chimera: a tool for functional high-throughput screening. Eur J Pharmacol 502: 31-40.
37. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, et al. (2007) In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74: 1172-1181.
38. Green WN, Ross AF, Claudio T, (1991) cAMP stimulation of acetylcholine receptor expression is mediated through posttranslational mechanisms. Proc Natl Acad Sci USA 88: 854-858.
39. Kuryatov A, Berrettini W, Lindstrom J, (2011) AChR α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)2α5 AChR function. Mol Pharmacol 79: 119-25.
40. Papke RL, Wecker L, Stitzel JA, (2010) Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 333: 501-518.
41. Xiao Y, Abdrakhmanova GR, Baydyuk M, Hernandez S and Kellar KJ (2009) Rat neuronal nicotinic acetylcholine receptors containing α7 subunit: pharmacological properties of ligand binding and function. Acta Pharmacol Sin 30, 842-850.
42. Yamauchi JG, Nemecz A, Nguyen QT, Muller A, Schroeder L, et al. (2011) Characterizing Ligand-Gated ion channel receptors with genetically encoded Ca++ sensors. PLoS one 6: e16519.